The following table sets forth the Company's interest expense incurred for the years ended December 31, 2021 and 2020: Year Ended December 31, 2021 2020 Related party Others Total Related party Others Total Accrued coupon interest expense $ 1,898 $ 2,278 $ 4,176 $ 550 $ 5,335 $ 5,885 Amortization of debt discounts 21 119 140 533 5,197 5,730 Amortization of deferred financing offering costs 57 426 483 14 733 747 Total convertible notes interest expense $ 1,976 $ 2,823 $ 4,799 $ 1,097 $ 11,265 $ 12,362 Note 12. Fair Value Measurements Liabilities measured at fair value on a recurring basis as of December 31, 2021 and 2020 consisted of the following: December 31, 2021 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 34,474 $ — $ — $ 34,474 December 31, 2020 Total fair value Quoted price in active markets for identical assets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Liabilities Bookings Commitment $ 32,651 $ — $ — $ 32,651 Interest make-whole derivative 4 $ — $ — $ 4 The Company’s intangible assets and goodwill are initially measured at fair value and any subsequent adjustment to the initial fair value occurs only if an impairment charge is recognized. Level 2 and 3 Inputs Bookings Commitment On August 3, 2017, the Company entered into an asset purchase agreement (the “APA”) with Allscripts Healthcare Solutions, Inc. (“Allscripts”), pursuant to which the Company agreed to sell to Allscripts substantially all of the assets of the Company’s provider/patient engagement solutions business, including the Company’s FusionFX solution and components of its NantOS software connectivity solutions (the “Business”). On August 25, 2017, the Company and Allscripts completed the sale of the Business (the "Disposition") pursuant to the APA. NantHealth, Inc. Notes to Consolidated Financial Statements (Dollars in thousands, except per share amounts) - 119 -
RkJQdWJsaXNoZXIy NTIzOTM0